<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590196</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0566</org_study_id>
    <secondary_id>096625</secondary_id>
    <secondary_id>098928</secondary_id>
    <nct_id>NCT04590196</nct_id>
  </id_info>
  <brief_title>Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients</brief_title>
  <official_title>Effect of Oral Curcumin Supplementation on Choriocapillaris and Drusen Characteristics Measured by Multimodal Retinal Imaging in Dry Age-related Macular Degeneration (AMD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VitreoRetinal Surgery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Illinois Society for the Prevention of Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nutrition plays an important role in preventing progression of dry age related macular&#xD;
      degeneration (AMD), a disease of aging that leads to drusen deposits in the macula causing&#xD;
      significant decrease in vision. Drusen contains amyloid protein which is inhibited by&#xD;
      curcumin, a natural plant based antioxidant. Oral Longvida curcumin has been shown to&#xD;
      accumulate in the retina of human subjects within 10 days of supplementation. This study aims&#xD;
      to investigate the duration of oral curcumin supplementation needed to see clinical impact in&#xD;
      reducing volume and number of drusen and decreasing choriocapillaris density loss or flow&#xD;
      impairment in dry AMD patients. Patients will be given a 12-month course of oral Longvida&#xD;
      curcumin and clinical impact will be measured by multimodal retinal imaging (fundus photos,&#xD;
      OCT and OCT-A) at day 0, month 3, month 6, and month 12 of supplementation. Previous small&#xD;
      studies have shown change in drusen size within 4 6months of curcumin supplementation, given&#xD;
      that drusen can naturally fluctuate in size, we want to have a longer study period with a&#xD;
      control group to better understand the effects of curcumin on drusen characteristics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drusen volume</measure>
    <time_frame>baseline, 3month, 6month, 12 month timepoints</time_frame>
    <description>Quantify change in volume of drusen/drusenoid pigment epithelial detachments at day 0, month 3, month 6, month 12 by comparing fundus photos and OCT images obtained at these time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drusen size</measure>
    <time_frame>baseline, 3month, 6month, 12 month timepoints</time_frame>
    <description>Quantify change in size of drusen/drusenoid pigment epithelial detachments at day 0, month 3, month 6, month 12 by comparing diameter of drusen in OCT images obtained at these time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Longvida curcumin</intervention_name>
    <description>longvida curcumin verdure sciences formulation</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Composition of Placebo :&#xD;
95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 50 years old BCVA 20/20 to 20/400 Dry AMD with many large (&gt;300 μm in diameter&#xD;
             and more than 100 μm in height) soft drusenoid PEDs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence (or history) of significant geographic atrophy or choroidal&#xD;
             neovascularization in either eye; history of eye surgery (other than cataract&#xD;
             extraction) within 90 days, history of BRVO/CRVO, Macular hole, pathologic myopia,&#xD;
             uveitis, pseudovitelliform maculopathy will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajvi Mehta, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajvi Mehta, MD</last_name>
    <phone>312-970-1806</phone>
    <email>mehta@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Lim, MD</last_name>
    <phone>312-996-6562</phone>
    <email>jennylim@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Illinois eye and ear infirmary</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajvi Mehta, MD</last_name>
      <phone>312-970-1806</phone>
      <email>mehta30@uic.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Rajvi Mehta</investigator_full_name>
    <investigator_title>Resident Physician Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

